The expression of resistance to cephalosporins is highly varied and due to various mechanisms. The greatest disadvantage of the cephalosporins is that they are inactivated by the array of 0-lactamases produced by bacteria. The high levels of chromosomal enzymes produced by these organisms are a major cause of cephalosporin resistance. Plasmid-mediated f3-lactamases (PMBLs) have also been implicated as causes of resistance, and other cephalosporinases have been described. Point mutations of specific amino acids of well-recognized PMBLs (e.g., TEM-1 and SHV-1) have also produced enzymes capable of attacking a wider spectrum of 0-lactam agents. The availability of newer 0-lactams may be conducive to the development of such 0-lactamases, in which chromosomal and newer plasmid derivatives that may or may not contain the AmpC gene are selected. The occurrence of such enzymes is likely to continue to increase.
Many new cephalosporins have been developed over the past two decades as a result of structural modifications to the cephalosporin nucleus. These modifications were made to facilitate the production of compounds with greater antibacterial activity and improved pharmacological properties and to overcome the bacterial resistance that seems to arise quite rapidly. Bacterial resistance to /3-lactam antibiotics is due to reduced permeation of the drugs through the outer cell membrane, inactivation of the compounds by /3-lactamases, and the inability of the compounds to bind to target penicillin-binding proteins (PBPs) that have been altered.
Altered Membrane Permeability and/or PBPs
Resistance due to reduced permeability and altered target sites has not developed as rapidly as has resistance resulting from the production of a variety of 0-lactamases. Reduced permeability, a characteristic that is important primarily in gram-negative bacteria [1] , is mainly mediated by the loss or modification of the outer membrane porin and involves the 35-50-kD proteins (table 1) [2] [3] [4] [5] [6] . However, the absence of a porin such as the F or the C porin does not necessarily confer cross-resistance to all cephalosporins [7] ; some cephalosporins are affected to a greater extent than others. An F porin mutation may confer resistance to the newer cephalosporins such as cefmenoxime, cefepime, ceftazidime, and cefuroxime.
Altered PBPs that are associated with /3-lactam resistance are more common in gram-positive bacteria than in gram-negative bacteria [8] . Most altered PBPs have decreased affinity for 0-lactanis and have been found in many different organisms (table 2) [8, 9] . The best example of PBP-mediated resistance is methicillin-resistant Staphylococcus aureus. This organism overproduces PBP 2a, which has a low affinity for /3-lactams. Streptococcus pneumoniae produces PBPs I a, 2a, 2x, and 2b. Altered PBPs 1 a and 2x are implicated in resistance to expanded-spectrum cephalosporins [8] . This PBP-mediated resistance has been shown to be transferable to susceptible strains [10] . /3-lactam-resistant viridans streptococci have an altered PBP 2b that is identical to that present in pneumococci; this finding suggests a lateral transfer of this gene from the pneumococci [11] .
Clinical resistance of gram-negative bacteria to /3-lactams is rarely associated with PBPs, possibly because the /3-lactamases are highly effective in producing resistance. The only reports of PBP-mediated resistance in these bacteria involved laboratory mutants of Escherichia coli and implicated PBP 2 (for mecillinam resistance) and PBP 3 (for cephalexin resistance) [12, 13] . Similar resistance has not been found in other Enterobacteriaceae. PBP 3 has been implicated in resistance to cefsulodin in Pseudomonas species [14] , while resistance to cefoxitin has been associated with PBPs 1 and 2 in anaerobic Bacteroides species [3] .
fl-lactamase-Mediated Resistance
It appears probable that all bacteria produce f3-lactamases (usually chromosomal) that are specific to the subspecies level [15] . These /3-lactamases play some role in normal bacterial physiology. Of concern are the "true" /3-lactamases, which are able to hydrolyze /3-lactam antibiotics and affect the clinical use of these compounds. These chromosomal enzymes may be produced at high levels constitutively or by induction. In addition, bacteria may also carry R plasmids specific for /3-lacta- mases that are different from the chromosomally mediated enzymes.
The greatest clinical problem associated with use of the cephalosporins is the fact that they are inactivated by the vast and still-evolving array of /3-lactamases produced by gramnegative bacteria. Since the introduction of cephalosporins in the 1960s, plasmid-mediated f3-lactamases have been produced by Enterobacteriaceae, pseudomonads, and other gram-negative organisms such as Haemophilus and Neisseria species.
Because the array of known and yet-to-be-discovered /3-lactamases is vast, classification of these enzymes is essential. Several schemes for classifying 0-lactamases have been proposed (table 3) [16] [17] [18] [19] . Some investigators are more comfortable with Ambler's classification [18] because of its molecular basis, which facilitates study of the sequence of newly discovered /3-lactamases. This type of classification is more stable than the phenotypic classification of Bush and co-workers [19] . However, there is presently good agreement between the two classifications, with the exception of Bush's group 2d (cloxacillinases), which had also included class A enzymes of Actinomadura and Streptomyces together with the class D types.
The "early" (3-lactamases such as the TEM and SHV types have further evolved into the so-called extended-spectrum /3-lactamases (ESBLs), which are capable of inactivating extended-spectrum cephalosporins, such as those with aminothia- [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . However, these enzymes vary considerably in the levels at which they express resistance to various cephalosporins (table 5) [30, 31] . As is suggested by these data, SHV-derived enzymes appear to confer much higher resistance than do TEM-derived enzymes. The enzymes that are active against cephalosporins are listed in table 6 [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] . Some of these enzymes include those derived from the plasmid-mediated TEM or SHV types. These derivatives are not strictly cephalosporinases because they act on penicillins as well. However, some of these derivatives hydrolyze the cephalosporins better than they hydrolyze penicillins.
Several other plasmid-mediated (but not TEM-or SHVderived) ESBLs that affect cephalosporins have also been identified. CEP 1 was reported in Proteus mirabilis even before the introduction of new cephalosporins in 1976 [32] . Most of these extended-spectrum /3-lactamases do not confer resistance to the cephamycins. However, enzymes such as MIR-1, Table 4 . Substitution in amino acids among extended-spectrum 0-lactamases. [20] ; data are from [21] [22] [23] [24] [25] [26] [27] [28] [29] . Ala = alanine; Arg = arginine; Asp = aspartic acid; Gln = glutamine; Glu = glutamic acid; Gly = glycine; His = histidine; Leu = leucine; Lys = lysine; Met = methionine; Ser = serine; Thr = threonine.
CMY-1, and CMY-2, which can be found in E. coli and Klebsiella pneumoniae, are able to confer high-level resistance to the cephamycins [31, 36] .
Also included among the "plasmid-mediated" cephalosporinases are those that appear to have been derived from the chromosomal AmpC-type source. BIL-1 and FEC-1, which are found in E. coli, are predominantly cephalosporinases [34, 35] . The FUR enzyme found in E. coli and K pneumoniae confers resistance to ceftazidime [40] . In 1988, investigators in Japan detected a plasmid-mediated enzyme responsible for resistance to 0-lactams (including imipenem) in Pseudomonas aeruginosa [48] . More recently, outbreaks of strains of Serratia [53, 54] . Arg = arginine; Asn = asparagine; Asp = aspartic acid; Cys = cysteine; Ile = isoleucine; IRT = inhibitor-resistant TEM; Leu = leucine; Met = methionine; Ser = serine; Trp = tryptophan; Val = valine.
* Amino acid positions are numbered according to [20] .
marcescens that are highly resistant to broad-spectrum 0-lactams and carbapenems have been reported from Japan and were found to be caused by a plasmid-mediated metallo-/3-lactamase [50] . Other cephalosporinase enzymes that should be considered are the carbapenemases, since some of these enzymes confer resistance to some, if not all, cephalosporins. The classic plasmid-mediated /3-lactamases are usually inhibited by /3-lactamase inhibitors. Some of the enzymes that are active against the cephalosporins are resistant to the action of the inhibitors [51, 52] . The TEM-derived enzymes, designated TRI (TEM resistant to inhibitors) or IRT (inhibitorresistant TEM), are in this group. These enzymes have amino acid mutations at positions different from those in inhibitorsusceptible enzymes (table 7) [53, 54] . The mutations occur mainly at positions 67, 241, and 272 (Sutcliffe numbering [20] ).
It had been suggested that the substitution of methionine at position 67 by other amino acids caused a decrease in enzyme affinity for the inhibitors clavulanate or sulbactam. This decrease occurred because position 67 is close to the active site of 0-lactamase, which is serine at position 68 [55] .
Diverse genes are capable of single-point mutations or multiple-combination mutations that encode for the production of /3-lactamases with changing spectra of 0-lactam substrates. Palzkill and associates [56] [57] [58] [59] have reported a multiplicity of possible amino acid substitutions.
Resistance to the newer cephalosporins may also emerge as a result of the expression of the chromosomal 0-lactamases that may be induced in many gram-negative organisms such as P. aeruginosa, Enterobacter species, Morganella species, Citrobacter species and Serratia species. Fortunately, many of the cephalosporins, although labile to hydrolysis, are not strong inducers of the enzymes, failing to induce below their MICs and resulting in susceptible 0-lactamase -inducible strains.
However, the expression of high levels of these enzymes can be maintained by derepressed mutants that may arise spontaneously or may be selected during therapy with some cephalosporins. Livermore [60] and Sanders [61] have both stated that f3-lactamase-derepressed mutants may be selected from inducible populations during therapy with labile weak inducers. The susceptible inducible cells are killed, allowing the survival of derepressed mutants.
Of course, selection depends on the type of f3-lactam used as well as the density of the bacterial population present at the infected site. Some antibiotics may be more prone to foster selection of derepressed or extended-spectrum enzyme-producing strains than are others. For example, the use of ceftazidime or cefotaxime in laboratory experiments is more likely to result in selection for resistant P. aeruginosa than is the use of cefepime; mutation to cefepime resistance is <4.5 X 10 -" at four or eight times the MIC of cefepime, whereas mutation to ceftazidime resistance is 3.4 X 10 7 at eight times the MIC of ceftazidime [62] .
The causal relationship between the use of a specific antibiotic and the emergence of resistant strains in hospital flora is often difficult to establish. However, outbreaks of particular types of resistance have occurred after increased use of a particular antibiotic, especially when the drug is used as empirical monotherapy [27] . Such outbreaks tend to cease when the antibiotic is used less or its use is discontinued.
Epidemiological Perspective
In the recent past, TEM-1, TEM-2, SHV-1, OXA-1, PSE-1, and PSE4 had little activity against most of the newer cephalosporins [63] . As mentioned above, the growing emergence of ESBLs, most of which are mutants of TEM-1, TEM-2, and SHV-1, has been observed during the past decade [64, 65] . These enzymes now confer resistance to many of the newer cephems, monobactams, and penicillins that are used to treat gram-negative bacterial infections [64, 65] .
The ESBLs found most commonly in Klebsielleae were first reported in France in the mid 1980s [66, 67] . By 1994, investigators working with the National Nosocomial Infections Surveillance System reported that 8% of Klebsielleae in the United States were producing ESBLs [68, 69] . ESBLs are currently being detected with increasing frequency in other Enterobacteriaceae besides Klebsielleae [64, 65, 69, 70] .
While ESBLs were first recognized in Europe in 1983, they have increasingly been reported in many countries, including those in the western Pacific and India (table 8) [65, 71] . However, some types of enzymes are confined to certain countries, which may suggest local dissemination. For example, both TEM-10 and TEM-12 are found mainly in the United States but have been rare or absent in continental Europe [65] . Whether a particular pattern exists for the occurrence of 0-lactamases within Asia and the western Pacific countries needs to be determined. In general, resistant strains most commonly emerge at sites or in geographic areas where antibiotic use is most frequent [72, 73] . In contrast, rates of resistance are often low among the general wards of community hospitals in developed countries. These differences may be explained in terms of the degree of selection pressure associated with antibiotic use. However, rates of 0-lactamase-mediated resistance also vary considerably among community-acquired pathogens from different geographic sources.
For example, nearly 30% of isolates of H. influenzae from Spain [74, 75] and Taiwan [76] produce f3-lactamases, whereas fewer than 5% of those from Austria and Germany produce these enzymes [74, 75] . These geographic variations can be explained in large part by the common use of antibiotics in the community as well as their over-the-counter availability in both Spain and Taiwan. However, there may be other factors that influence resistance rates, as evidenced by the fact that neither of the above conditions in Spain and Taiwan apply to Canada, where 29% of H. influenzae isolates produce /3-lactamases [77] .
Conclusion
New types of cephalosporin resistance will inevitably occur in the future, even with the development of new cephalosporins. Resistance due to new, plasmid-mediated /3-lactamases seems to have developed rapidly over the past decade and may have resulted from more frequent use of some of the newer cephalosporins. Although these extended-spectrum f3-lactamases confer resistance to a wide range of /3-lactams, they can be inhibited by the /3-lactamase inhibitors clavulanate, sulbactam, and tazobactam [78] . The combinations of a /3-lactam, including cephalosporins, and an inhibitor will be effective against organisms producing such enzymes. There have been few reports of the occurrence of organisms that produce IRT enzymes. /3-lactamases, including those that are chromosomally mediated, will remain a problem in many regions especially those regions in which the selection pressure of antibiotics is maintained. Therefore, it will be crucial to ensure that proper surveillance of antibiotic use is in place and that the data acquired from such surveillance are used to help establish appropriate guidelines and policies for the use of antibiotics, particularly the /3-lactams.
